Haemonetics Q1 Earnings Call Highlights
Haemonetics (NYSE:HAE) reported Q1 interventional technologies returning to 3% organic growth, with vascular closure led by VASCADE MVP and MVP XL momentum in the U.S. Apheresis revenue rose 6% organically to $191M and plasma revenue grew 8% organically as Persona PLUS rollout accelerates. Haemonetics raised FY2027 revenue guidance to 5% to 8% reported and 4% to 7% organic.
How this was made
The 30-second read
Why it matters
Traders can use the raised FY2027 revenue outlook, early adoption yield gains, and reaffirmed cash-flow conversion target to update models for growth and profitability trajectory, while monitoring margin headwinds and the scope of contracted deployments.
Market read
The article is a guidance and adoption-metrics update from Haemonetics’ Q1 call, with multiple forward-looking signals that can drive near-term estimate revisions.
What to watch
Persona PLUS rollout is ahead of schedule but guidance only includes contracted deployments with committed timelines; upside may be constrained if center conversions slow or tariff recovery assumptions prove optimistic.
Background
The piece summarizes Haemonetics’ Q1 earnings call, focusing on interventional technologies growth, Persona PLUS plasma rollout, margin/cash flow, and updated FY2027 guidance.
Ticker impact
Haemonetics raised fiscal 2027 revenue growth guidance to 5% to 8% reported and 4% to 7% organic, citing Q1 outperformance and VASCADE/PERSONA PLUS momentum.
Moderately positive bias for the stock as traders reprice FY27 growth and margin/cash-flow durability.
The article contains multiple forward-looking datapoints: raised revenue guidance, reaffirmed FCF conversion target, and specific adoption/yield metrics (Persona PLUS early adopters, VASCADE MVP XL momentum). It does not provide EPS or consensus beats, limiting precision on magnitude.
Market effects
Supports sentiment for blood management and apheresis equipment/software adoption, particularly PFA access-site growth and plasma yield optimization.
Highlights stronger North American collections and mid-20% North American disposables growth, which may influence regional demand expectations.
Reinforces global plasma disposable growth and European double-digit sales, relevant for peers exposed to plasma collection economics.
Counterpoint
Gross margin was down 40 bps YoY and operating margin down 70 bps, so the guidance raise may be partially offset by cost pressures and mix effects.
Key entities
- companyHaemonetics
Blood management solutions provider; reported Q1 metrics and raised FY2027 revenue guidance, citing VASCADE MVP XL momentum and Persona PLUS rollout.
- productVASCADE MVP and VASCADE MVP XL
Interventional technologies platform; described as gaining momentum in the U.S. and benefiting from expanded indication up to 17 French.
- productPersona PLUS
Firmware upgrade for plasma yield and productivity; rollout ahead of schedule with early adopters reporting yield gains exceeding 5%.
- clinical_evidenceEmory University real-world study
Study of more than 1,600 patients using VASCADE MVP XL in large-bore sheath procedures, reporting rapid hemostasis and >92% same-day discharge.
